Boston Scientific Corporation BSX

43.92 (0.76) (1.70%) as of 25 Sep
Market cap
$64.7B
P/E
17.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Boston Scientific Corporation (BSX) Revenue growth

Boston Scientific Corporation's revenue growth over the twelve months to 30 June 2026 was 13.5%, down 6.4 percentage points from fiscal 2025 (19.9%). Over the past ten years it has ranged from −7.66% (fiscal 2020) to 19.9% (fiscal 2021); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of 8.80% and above the Healthcare sector median of 8.26%.

Revenue growth, annual

Annual

Period Revenue growth Change (points)
FY2025 19.9% 2.26
FY2024 17.6% 5.32
FY2023 12.3% 5.61
FY2022 6.68% (13.24)
FY2021 19.9% 27.58
FY2020 −7.66% (16.94)
FY2019 9.28% 0.71
FY2018 8.57% 0.68
FY2017 7.89% (4.27)
FY2016 12.2% 10.85

Quarterly

Period Revenue growth Change (points)
Jun 2026 7.53% (4.05)
Mar 2026 11.6% (4.27)
Dec 2025 15.9% (4.49)
Sep 2025 20.3% (2.50)
42 more quarters

Against its own ten years

Low −7.66% High 19.9%
Ten-year median 9.28%
Current reading's percentile 91

Revenue growth against peers

Company Revenue growth
DXCM DexCom, Inc. compare 15.5%
EW Edwards Lifesciences Corporation compare 14.6%
BSX Boston Scientific Corporation 13.5%
MDT Medtronic PLC compare 9.77%
PHG Koninklijke Philips N.V. compare 9.11%
SYK Stryker Corporation compare 8.48%
STE STERIS plc compare 8.37%
ABT Abbott Laboratories compare 8.06%
GEHC GE HealthCare Technologies Inc. compare 6.51%
Medical Devices industry median 8.80%
Healthcare sector median 8.26%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on BSX